Emmaus Life Sciences, Inc. · OTC:EMMA
Emmaus Life Sciences — MYnd Analytics — Investor Presentation (May 2018)
25 slides from Emmaus Life Sciences's investor presentation, May 22, 2018
Slide 1: MYnd Analytics Investor Presentation May 2018
mynd analytics GREATER ACCESS TO MORE EFFECTIVE TREATMENTS REDUCES TOTAL COST OF CARE NASDAQ: MYND Investor Presentation ‘May 2018
Slide 2: Disclaimer
*, DISCLAIMER This presentation contains “forward-looking statements” pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995 that include information relating to future events, future financial performance, strategies, expectations, competitive environment, re
Slide 3: MYnd Analytics (NASDAQ:MYND)
» MYND ANALYTICS (NASDAQ:MYND) Unique first mover in treating mental health conditions through the combination of telemedicine and data analytics/artificial (augmented) intelligence to improve health care delivery and reduce costs. Telemedicine
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS ¥ Initial focus is the $147 billion underserved mental health market! © Highest worldwide disease burden and single largest reason for work disability © Over $6k additional yearly health care costs for individuals not adequately treated for co-morbid behavioral health diagnosis
Slide 5: Mental Health - Incidence & Cost
MENTAL HEALTH - INCIDENCE & COST Mental disorders, including substance abuse, have the highest estimated annual health spending in the U.S. + Globally, an estimated 300 milion people suffer from depression and 60 milion have Bipolar affective disorder.") + Anxiety disorders are the most common menta
Slide 6: Economic Impact (in 2012)
, ECONOMIC IMPACT (IN 2012) hw Per-member per- Increase in with Behavioral | month (PMPM) cost | PMPM with BH | Total PMPM Population Health (BH) u EN wt M Gas without BH jiagnosis with BH Diagnosis Diagnosis Commercial 15% $340 $941 276% Medicare 9% $582 $1429 245% Medicaid 20% $381 $1301 341% All
Slide 7: Trial and Error Pharmacotherapy
TRIAL AND ERROR PHARMACOTHERAPY 7 Millions of Americans have failed two or more therapeutics for mental illness and are considered resistant to treatment “Current medications are not sufficient for most patients... We still do not know who will respond to a specific treatment. Even for the fraction
Slide 8: Service Lines
SERVICE LINES [ Problem \ Looming crisis in access to care: + Psychiatrist shortage + Waiting lists are high + 70% of mental health is treated by PCPs + Low attendance and adherence to treatment (avg = 2 visits) Clinicians often rely on trial and error prescribing for depression, anxiety, PTSD and o
Slide 9: Telepsychiatry Arcadian
TELEPSYCHIATRY ARCADIAN telepsychiatry The Market The Process + Telemedicine is one of the fastest * Telepsychiatry involves the use of video growing areas of healthcare services conferencing and telecommunication today equipment to conduct real time mental health + The global telemedicine market is
Slide 10: Arcadian
ARCADIAN eee + Arcadian specializes in the delivery of mental health services through a network of social workers, therapists and psychiatrists throughout the United States + Offers a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand
Slide 11: Healthcare AI Market
HEALTHCARE Al MARKET + According to Accenture, when combined, key clinical health artificial intelligence (Al) applications can potentially create $150 billion in annual savings for the United States healthcare economy by 2026" + Injust the next five years, the health Al market is expected to grow m
Slide 12: EEG and the PEER Report
+ An electroencephalogram (EEG) is a completely painless. non-invasive test that records your brain's electrical activity and provides a basis for comparison against others within the Psychiatric Electroencephalography Evaluation Registry (‘PEER’) database + MYnd utilizes , thereby improving patient
Slide 13: Interim Findings from the Clinical Trial - Walter Reed PEER Trial
° INTERIM FINDINGS FROM THE 47 CLINICAL TRIAL — WALTER REED PEER TRIAL Improvement Over Standard of Care “') + 144% more improvement in QIDS- SR16 depression scores + 75% greater improvement in CHRT-7S scores for suicidal ideation + 139% greater improvement in PCL scores for PTSD (1) VAIDOD Clinical
Slide 14: Independent Validation
* INDEPENDENT VALIDATION From a rapidly growing research base, 100 peer-reviewed studies* of Quantitative EEG (QEEG) neurometrics (n = 6,025) have demonstrated the utility of these markers, including: + 12 randomized controlled trials of QEEG neurometrics for predicting medication response (n = 2,08
Slide 15: What Doctors Say
. WHAT DOCTORS SAY “Why are we treating an organ, the brain, without measuring the effect of our treatment on the organ? There are over 100 medications available for the treatment of behavioral disorders. The core problem is not that we need three more, the problem is that we need to know how to use
Slide 16: Target Business Model: Payors
TARGET BUSINESS MODEL: PAYORS VAIMilitary ee e) Payers and health systems Where suicide rates are seeking to improve clinical high and need for innovative __ International — outcomes and lower health and effective mental health single payer countries care costs care is high Case study: Horizon Healt
Slide 17: Patient Direct and Multi-Practice Provider Groups
Patient Direct Multi-Practice Provider Groups Direct Mutti-practitioner provider Over 15% of patients have groups seeking to provide 60% of individuals do not mental health concerns but value-based care and cutting receive care in mental health expertise not present to edge objective measurement add
Slide 18: Experienced Leadership
. EXPERIENCED LEADERSHIP Management Team Board of Directors George C. Carpenter, IV - President & CEO + Over 25 years of experience in healthcare technology and business development ‘+ MBA in Finance from the University of Chicago, BA from Dartmouth College Brian MacDonald ~ Chief Technology Officer
Slide 19: Milestones: Month Goals
. MILESTONES: 12 MONTH GOALS Establish 2" paid pilot program(s) with managed care companies and health systems seeking to improve clinical outcomes and lower health care costs Publish pharmacoeconomic benefits when providers use the PEER report on- line tool Penetrate VA and Military where suicide r
Slide 20: Capitalization & Balance Sheet
*, CAPITALIZATION & BALANCE SHEET Common Stock Issued and Outstanding (5/15/18) 5,676,191 Series A Preferred 1,050,000 Total Shares of Common Stock Underlying Issued Options 554,059 Average Strike Price: $5.14 Total Shares of Common Stock Underlying Issued Warrants 5,617,481 Average Strike Price: $4
Slide 21: Summary
. SUMMARY With telemedicine, we can deliver mental health services where and when the patient needs them including the privacy of one’s own home. With artificial intelligence, machine learning and data analytics, we can analyze massive quantities of data to recognize patterns, predict outcomes and p
Slide 22: MYnd Analytics Contacts
mynd e mynd analytics Robin LSmith, MD, MBA, Chairman of the Board tel: 917-691-7409 email: robin@robinismith.com George C. Carpenter IV, President and Chief Executive Officer tel: 949-697-2161 email: gcarpenter@myndanalytics.com Don D'Ambrosio, Chief Financial Officer tel: 949-420-4402 email: dambr
Slide 23: Digital Health Care: Investments
», DIGITAL HEALTH CARE: INVESTMENTS MYND is in one of the hottest areas of Al/digital health care (Gd AVN HEALTHCARE: CATEGORY HEATMAP DIAGNOSTICS AND ‘ 5 RISK ANALYTICS DRAW ‘cATEGORY 2012 20132014215. BNG MOST DEALS IN 2016 Inia & Risk Antes raging eiceegrcsiics Lifestyle Management & Montosng dom
Slide 24: Digital Health Care: 2016 Acquisitions
*. DIGITAL HEALTH CARE In 2016 the 10 largest acquisitions brought in over $11B for shareholders Acquired By Acquisition Amount Change Healthcare McKesson $3.0B Truven Analytics IBM $2.6B eResearchTechnology Nordic Capital $1.8B Netsmart Technologies Allscripts $950M Brightree Resmed $800M Imprivata
Slide 25: Mental Health - Today
MENTAL HEALTH - TODAY Problem: + There is a shortage of psychiatrists so most treatment for non- psychotic mental health disorders is delivered by non- psychiatrists.2 + Clinicians often rely on trial and error prescribing for depression, anxiety, PTSD and other mental health conditions 23 naivduais